U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H10N6O
Molecular Weight 182.1832
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DACARBAZINE

SMILES

CN(C)\N=N\C1=C(N=CN1)C(N)=O

InChI

InChIKey=FDKXTQMXEQVLRF-ZHACJKMWSA-N
InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+

HIDE SMILES / InChI

Molecular Formula C6H10N6O
Molecular Weight 182.1832
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DTIC-DOME

Approved Use

Dacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.

Launch Date

1975
Primary
DTIC-DOME

Approved Use

Dacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.

Launch Date

1975
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.2 μg/mL
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14.8 μM × min
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41.4 min
750 mg/m² single, intravenous
dose: 750 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACARBAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
DACARBAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503, 504
unhealthy, 34–79
n = 3
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 3
Sources: Page: p.503, 504
Disc. AE: Cerebral ischemia...
AEs leading to
discontinuation/dose reduction:
Cerebral ischemia (grade 4, 33%)
Sources: Page: p.503, 504
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
DLT: Thrombocytopenia...
Disc. AE: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 2, 6.25%)
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 1, 6.25%)
Sources: Page: p.503
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Other AEs: Neutropenia, Fatigue...
Other AEs:
Neutropenia (grade 4, 2.2%)
Fatigue (grade 4, 2.2%)
Sources: Page: p.5
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Disc. AE: Leukopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia (grade 3-5)
Thrombocytopenia (grade 3-5)
Anemia (sometimes)
Hematopoiesis impaired
Hepatotoxicity (grade 3-5, 0.01%)
Hepatic vein thrombosis (grade 3-5, 0.01%)
Necrosis hepatocellular (grade 3-5, 0.01%)
Anaphylaxis
Sources:
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Disc. AE: Anemia, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Anemia (mild)
Leukopenia (grade 3-5)
Thrombocytopenia (grade 3-5)
Hepatotoxicity (grade 3-5)
Hepatic vein thrombosis (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cerebral ischemia grade 4, 33%
Disc. AE
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503, 504
unhealthy, 34–79
n = 3
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 3
Sources: Page: p.503, 504
Thrombocytopenia grade 1, 6.25%
Disc. AE
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
Thrombocytopenia grade 2, 6.25%
DLT
800 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 800 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 1 times / 3 weeks
Co-administed with::
Lenalidomide, p.o(5 mg/day; 14 days)
Sources: Page: p.503
unhealthy, 34–79
n = 16
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 34–79
Sex: M+F
Population Size: 16
Sources: Page: p.503
Fatigue grade 4, 2.2%
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Neutropenia grade 4, 2.2%
1000 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 1000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 1 times / 3 weeks
Sources: Page: p.5
unhealthy, 40–65
n = 45
Health Status: unhealthy
Condition: Malignant melanoma
Age Group: 40–65
Sex: M+F
Population Size: 45
Sources: Page: p.5
Anaphylaxis Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hematopoiesis impaired Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatic vein thrombosis grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatotoxicity grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Necrosis hepatocellular grade 3-5, 0.01%
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Leukopenia grade 3-5
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Thrombocytopenia grade 3-5
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Anemia sometimes
Disc. AE
250 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 250 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
unhealthy
Hepatic vein thrombosis grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Hepatotoxicity grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Leukopenia grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Thrombocytopenia grade 3-5
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Anemia mild
Disc. AE
850 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim
PubMed

PubMed

TitleDatePubMed
Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
1975 Apr
Peripheral DTIC neurotoxicity: a case report.
1987
Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
1989 May
Dana-Farber Cancer Institute studies in advanced sarcoma.
1990 Feb
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
2000 Dec 15
Toxicity, mutation frequency and mutation spectrum induced by dacarbazine in CHO cells expressing different levels of O(6)-methylguanine-DNA methyltransferase.
2000 Feb 14
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
2000 Jan
Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase.
2000 Oct
Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice.
2001
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
2001 Dec
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
2001 Feb
Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
2001 Jul-Aug
[Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
2002
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
2002
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
2003
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
2003 Aug
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
2003 Feb 20
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
2003 Feb 24
Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
2003 Jan
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
2003 Jan 13
Metastatic melanoma presenting as cardiac mass and hemobilia.
2003 Mar
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
2003 Oct 20
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
2004 Jun 1
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
2005 Jun
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
2005 Sep 20
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
2006
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
2006 Jul 1
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
2007
Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
2007
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
2007 Jul
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
2007 Jun
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
2007 Nov
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
2007 Oct
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
2007 Sep 1
The management of desmoids in patients with familial adenomatous polyposis (FAP).
2008
Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia.
2008 Feb
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
2008 Jun
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells.
2008 Mar
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.
2008 Mar
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
2009 Jun
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Patents

Sample Use Guides

Malignant Melanoma: the recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals Hodgkin's Disease: The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.5 An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days
Route of Administration: Intravenous
The effect of alkyating agent dacarbazine (DTIC) and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). Growth inhibition in vitro was additive with the two drugs. There was no effect on drug uptake or on the number of DNA strand breaks. There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:09:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:09:29 GMT 2023
Record UNII
7GR28W0FJI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DACARBAZINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
DACARBAZINE [WHO-IP]
Common Name English
DIC
Common Name English
DTIC
Common Name English
DACARBASINE
Common Name English
dacarbazine [INN]
Common Name English
1H-IMIDAZOLE-4-CARBOXAMIDE, 5-(3,3-DIMETHYL-1-TRIAZENYL)-
Systematic Name English
DACARBAZINE [ORANGE BOOK]
Common Name English
Dacarbazine [WHO-DD]
Common Name English
DACARBAZINE [USP MONOGRAPH]
Common Name English
DACARBAZINE [HSDB]
Common Name English
DTIC-DOME
Brand Name English
DACARBAZINE [USP-RS]
Common Name English
DACARBAZINE [MI]
Common Name English
DACARBAZINE [VANDF]
Common Name English
DECARBAZINE
Common Name English
NSC-45388
Code English
NCI C04717
Code English
DACARBAZINE [IARC]
Common Name English
DACARBAZINE [EP MONOGRAPH]
Common Name English
IMIDAZOLE CARBOXAMIDE
Systematic Name English
DACARBAZINE [USAN]
Common Name English
DACARBAZINE [MART.]
Common Name English
DACARBAZINUM [WHO-IP LATIN]
Common Name English
DACARBAZINE [JAN]
Common Name English
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
Systematic Name English
BIOCARBAZINE R
Common Name English
DICARBAZINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C902
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
LIVERTOX NBK548913
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
WHO-ATC L01AX04
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
NDF-RT N0000175558
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
WHO-VATC QL01AX04
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1162308
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
DAILYMED
7GR28W0FJI
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
SMS_ID
100000088395
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
INN
3232
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
FDA UNII
7GR28W0FJI
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
DRUG BANK
DB00851
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
NSC
45388
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
LACTMED
Dacarbazine
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
WIKIPEDIA
DACARBAZINE
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
HSDB
3219
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
CAS
4342-03-4
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
NCI_THESAURUS
C411
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID0020369
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
PUBCHEM
135398738
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
ECHA (EC/EINECS)
224-396-1
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL476
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DACARBAZINE
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY Description: A colourless or pale yellow, crystalline powder.Solubility: Slightly soluble in water and ethanol (~750 g/l) TS.Category: Cytotoxic drug.Storage: Dacarbazine should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 8 ?C.Additional information: CAUTION: Dacarbazine must be handled with care, avoiding contact with the skin and inhalation ofairborne particles.
MERCK INDEX
m4065
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY Merck Index
CHEBI
4305
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
EVMPD
SUB06882MIG
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
MESH
D003606
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
DRUG CENTRAL
773
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY
RXCUI
3098
Created by admin on Fri Dec 15 16:09:29 GMT 2023 , Edited by admin on Fri Dec 15 16:09:29 GMT 2023
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
Km
METABOLIC ENZYME -> SUBSTRATE
Vmax
METABOLIC ENZYME -> SUBSTRATE
Vmax
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Km
METABOLIC ENZYME -> SUBSTRATE
Km
Related Record Type Details
METABOLITE INACTIVE -> PARENT
Plasma exposure to AIC was equivalent to that of DTIC, whereas urinary recovery of DTIC and AIC was low and highly variable.
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC